All questions
Question 1
A new oral medication for hypertension has a half-life of 24 hours and is administered once daily. The physician doubles the daily dose. Which of the following statements best describes the effect of this dose adjustment on the time to reach the new steady state and the resulting average steady-state concentration (Css,avg)?
- The time to reach steady state is halved, and the Css,avg is doubled.
- The time to reach steady state is unchanged, and the Css,avg is doubled. (correct answer)
- The time to reach steady state is doubled, and the Css,avg is quadrupled.
- The time to reach steady state is unchanged, and the Css,avg is increased but not doubled.
Explanation: The time required to reach steady state is determined by the drug's half-life and is independent of the dose. It takes approximately 4-5 half-lives to reach steady state, regardless of the dosing rate. Therefore, doubling the dose will not change the time to reach the new steady state. The average steady-state concentration (Css,avg) is directly proportional to the dosing rate. Therefore, doubling the maintenance dose will double the Css,avg.
Question 2
An oral medication is given once daily. At steady state, the peak concentration (Cmax) is measured to be 30 mg/L and the trough concentration (Cmin), measured 24 hours later just before the next dose, is 7.5 mg/L. What is the best estimate of this drug's elimination half-life?
- 6 hours
- 8 hours
- 12 hours (correct answer)
- 24 hours
Explanation: The concentration dropped from a peak of 30 mg/L to a trough of 7.5 mg/L over one dosing interval, which is 24 hours. A drop from 30 mg/L to 15 mg/L would be one half-life. A further drop from 15 mg/L to 7.5 mg/L would be a second half-life. Therefore, the concentration decreased by a factor of 4 (30 / 7.5), which means two half-lives have passed during the 24-hour dosing interval. The estimated half-life is 24 hours / 2 = 12 hours.
Question 3
To rapidly achieve a therapeutic plasma concentration of an antiarrhythmic drug, a physician administers a loading dose. The calculation of this loading dose is primarily based on which two pharmacokinetic parameters?
- Clearance and target steady-state concentration.
- Volume of distribution and target plasma concentration. (correct answer)
- Half-life and bioavailability.
- Clearance and volume of distribution.
Explanation: The loading dose (LD) is calculated to rapidly fill the volume of distribution (Vd) to a desired target plasma concentration (C_target). The formula is LD = (Vd * C_target) / F, where F is bioavailability. It is designed to achieve the therapeutic concentration immediately, bypassing the time it would normally take to reach steady state. Clearance determines the rate of elimination and is used to calculate the maintenance dose required to maintain that concentration, not the initial loading dose.
Question 4
A patient requires a loading dose of an antibiotic to rapidly achieve a target plasma concentration of 15 mg/L. The drug's volume of distribution (Vd) is estimated to be 0.6 L/kg. The patient weighs 70 kg. The drug is administered intravenously. What is the most appropriate loading dose?
- 420 mg
- 500 mg
- 630 mg (correct answer)
- 1750 mg
Explanation: The formula for a loading dose (LD) is LD = Vd * C_target. First, calculate the patient's total volume of distribution: Vd = 0.6 L/kg * 70 kg = 42 L. Then, calculate the loading dose: LD = 42 L * 15 mg/L = 630 mg. Since the drug is given intravenously, bioavailability (F) is 1 and does not need to be included in the calculation.
Question 5
To rapidly achieve a therapeutic plasma concentration of an antiarrhythmic drug, a physician administers a loading dose. The calculation of this loading dose is primarily based on which two pharmacokinetic parameters?
- Clearance and target steady-state concentration.
- Volume of distribution and target plasma concentration. (correct answer)
- Half-life and bioavailability.
- Clearance and volume of distribution.
Explanation: The loading dose (LD) is calculated to rapidly fill the volume of distribution (Vd) to a desired target plasma concentration (C_target). The formula is LD = (Vd * C_target) / F, where F is bioavailability. It is designed to achieve the therapeutic concentration immediately, bypassing the time it would normally take to reach steady state. Clearance determines the rate of elimination and is used to calculate the maintenance dose required to maintain that concentration, not the initial loading dose.
Question 6
A new antiepileptic drug is administered as 500 mg tablets, which have an oral bioavailability of 70%. The drug's volume of distribution is 50 L and its clearance is 4 L/hr. To rapidly achieve a therapeutic concentration of 14 mg/L, what is the most appropriate oral loading dose?
- 500 mg (1 tablet)
- 700 mg (1.4 tablets)
- 1400 mg (2.8 tablets)
- 1000 mg (2 tablets) (correct answer)
Explanation: Loading dose calculations are fundamental in pharmacology when you need to quickly achieve therapeutic drug concentrations. The key principle is that loading dose equals the desired concentration multiplied by the volume of distribution, then adjusted for bioavailability.
To find the oral loading dose, use this formula: Oral Loading Dose=BioavailabilityTarget Concentration×Volume of Distribution
Plugging in the values: Oral Loading Dose=0.7014 mg/L×50 L=0.70700 mg=1000 mg
This confirms that D) 1000 mg (2 tablets) is correct.
Let's examine why the other options are wrong:
A) 500 mg represents just one tablet without any pharmacokinetic calculations—this ignores both the target concentration and bioavailability considerations.
B) 700 mg is the result you'd get if you forgot to account for bioavailability (14 × 50 = 700), but since only 70% is absorbed, you need a higher oral dose.
C) 1400 mg appears to double the target concentration calculation, possibly confusing this with maintenance dose calculations or applying bioavailability incorrectly.
Study tip: Always remember that oral loading doses must be higher than IV loading doses due to incomplete absorption. When bioavailability is less than 100%, divide your calculated dose by the bioavailability fraction to determine the actual amount you need to administer orally. Question 7
A patient is started on a new medication with a half-life of 3 days. A loading dose is not administered. The patient is expected to reach approximately 94% of the final steady-state plasma concentration after how much time?
- 6 days
- 9 days
- 12 days (correct answer)
- 15 days
Explanation: The time to reach steady state is determined by the drug's half-life. After 1 half-life, 50% of steady state is reached. After 2 half-lives, 75% is reached. After 3 half-lives, 87.5% is reached. After 4 half-lives, 93.75% is reached. After 5 half-lives, ~97% is reached. To reach approximately 94% of steady state requires 4 half-lives. With a half-life of 3 days, the time required is 4 * 3 days = 12 days.
Question 8
A patient has been on a continuous intravenous infusion of a drug for 5 days and has achieved a stable steady-state concentration. A laboratory error leads to a report of a critically high drug level, and the infusion is stopped for 6 hours. After the error is discovered, the infusion is restarted at the original rate. Assuming the drug has a half-life of 12 hours, how long after restarting the infusion will it take to return to the original steady-state concentration?
- Approximately 6 hours
- Approximately 12 hours
- Approximately 24 hours
- Approximately 48-60 hours (correct answer)
Explanation: The time to reach steady state depends on the drug's half-life, not the starting concentration. When the infusion is restarted, the plasma concentration will begin to rise towards the original steady-state level. The time course for approaching this steady state is governed by the drug's half-life. It will take approximately 4-5 half-lives to get back to the original steady state, regardless of the concentration from which it started. With a half-life of 12 hours, this corresponds to 4 * 12 = 48 hours to 5 * 12 = 60 hours.
Question 9
A drug's elimination follows capacity-limited (Michaelis-Menten) kinetics. The drug is administered via continuous infusion. If the infusion rate is increased from a rate well below the Km to a rate that approaches the Vmax, what will be the most significant consequence for the time required to reach a steady state?
- The time to steady state will decrease because the drug concentration increases faster.
- The time to steady state will remain dependent only on the initial half-life.
- The time to steady state will increase disproportionately, possibly taking weeks or months. (correct answer)
- A true steady state will never be reached, regardless of the infusion rate.
Explanation: For drugs with capacity-limited elimination, as the dosing rate approaches the maximum rate of elimination (Vmax), the clearance of the drug decreases. This means the 'effective' half-life increases as concentrations rise. The time to reach steady state is a function of this effective half-life. As the system becomes saturated, the half-life prolongs dramatically, and thus the time to reach a new steady state increases disproportionately. It can take an extremely long time to reach steady state, and small changes in dose can lead to large changes in steady-state concentration.
Question 10
A drug is 90% eliminated by the kidneys and 10% by the liver. In a patient with normal renal function, its half-life is 4 hours. A patient presents with severe renal impairment, having a glomerular filtration rate that is one-third of normal. Assuming Vd is unchanged, what is the estimated new half-life of the drug in this patient?
- 8 hours
- 10 hours (correct answer)
- 12 hours
- 20 hours
Explanation: Let the normal total clearance be CL_T. Then CL_renal = 0.9 * CL_T and CL_hepatic = 0.1 * CL_T. In the patient with renal impairment, the new renal clearance is (1/3) * CL_renal = (1/3) * (0.9 * CL_T) = 0.3 * CL_T. Hepatic clearance is unchanged. The new total clearance is CL_new = (new CL_renal) + CL_hepatic = (0.3 * CL_T) + (0.1 * CL_T) = 0.4 * CL_T. Since half-life is inversely proportional to clearance (t1/2 ∝ 1/CL), the new half-life will be t1/2_new = t1/2_normal * (CL_T / CL_new) = 4 hours * (CL_T / (0.4 * CL_T)) = 4 hours * (1 / 0.4) = 4 hours * 2.5 = 10 hours.
Question 11
Drug A and Drug B have the same target therapeutic concentration. Drug A has a large volume of distribution (Vd) and a low clearance (CL). Drug B has a small Vd and a high CL. Which statement accurately compares the half-life (t1/2) and required loading dose (LD) for these two drugs?
- Drug A has a shorter t1/2 and requires a smaller LD than Drug B.
- Drug A has a longer t1/2 and requires a larger LD than Drug B. (correct answer)
- Drug A has a shorter t1/2 and requires a larger LD than Drug B.
- Drug A has a longer t1/2 and requires a smaller LD than Drug B.
Explanation: Half-life (t1/2) is directly proportional to the volume of distribution (Vd) and inversely proportional to clearance (CL), according to the formula t1/2 ≈ (0.693 * Vd) / CL. Drug A has a large Vd and low CL, both of which contribute to a longer half-life compared to Drug B (small Vd, high CL). The loading dose (LD) is directly proportional to Vd (LD = Vd * C_target). Since Drug A has a larger Vd, it will require a larger loading dose than Drug B to achieve the same target concentration.
Question 12
A 68-year-old male with chronic kidney disease (creatinine clearance of 30 mL/min, normal > 90 mL/min) is started on a new medication that is eliminated exclusively by the kidneys. The drug has a half-life of 6 hours in patients with normal renal function. Compared to a patient with normal renal function receiving the same dosing regimen, what changes in pharmacokinetic parameters are expected in this patient?
- Time to reach steady state will be shorter and steady-state concentration will be lower.
- Time to reach steady state will be longer and steady-state concentration will be higher. (correct answer)
- Time to reach steady state will be longer, but steady-state concentration will be unchanged.
- Time to reach steady state will be unchanged, but steady-state concentration will be higher.
Explanation: Reduced renal function decreases drug clearance (CL). Since half-life (t1/2) is inversely proportional to clearance (t1/2 ≈ 0.693 * Vd/CL), a lower CL will result in a longer half-life. The time to reach steady state is directly proportional to the half-life (approximately 4-5 half-lives), so it will be longer. Steady-state concentration (Css) is inversely proportional to clearance (Css = Dosing Rate / CL). Therefore, with the same dosing regimen, a lower CL will lead to a higher steady-state concentration.
Question 13
A drug is administered orally every 12 hours. Its half-life is 12 hours, and it follows first-order kinetics. The dosing regimen is changed to give the same total daily dose, but now administered every 24 hours (i.e., double the dose, once a day). How will this change affect the average steady-state concentration (Css,avg) and the fluctuation between peak and trough concentrations at steady state?
- Css,avg will remain the same, but fluctuation will decrease.
- Css,avg will increase, and fluctuation will increase.
- Css,avg will remain the same, but fluctuation will increase. (correct answer)
- Css,avg will decrease, and fluctuation will decrease.
Explanation: The average steady-state concentration (Css,avg) is determined by the total daily dose (dosing rate) and clearance. Since the total daily dose is unchanged, the Css,avg will also remain the same. However, the fluctuation (the difference between peak and trough concentrations) is highly dependent on the dosing interval relative to the half-life. By doubling the dosing interval from 12 hours (1 half-life) to 24 hours (2 half-lives), more drug will be eliminated between doses, leading to a lower trough, and a larger dose will be given, leading to a higher peak. Therefore, the fluctuation will increase significantly.
Question 14
An oral medication is given once daily. At steady state, the peak concentration (Cmax) is measured to be 30 mg/L and the trough concentration (Cmin), measured 24 hours later just before the next dose, is 7.5 mg/L. What is the best estimate of this drug's elimination half-life?
- 6 hours
- 8 hours
- 12 hours (correct answer)
- 24 hours
Explanation: The concentration dropped from a peak of 30 mg/L to a trough of 7.5 mg/L over one dosing interval, which is 24 hours. A drop from 30 mg/L to 15 mg/L would be one half-life. A further drop from 15 mg/L to 7.5 mg/L would be a second half-life. Therefore, the concentration decreased by a factor of 4 (30 / 7.5), which means two half-lives have passed during the 24-hour dosing interval. The estimated half-life is 24 hours / 2 = 12 hours.
Question 15
A drug is 90% eliminated by the kidneys and 10% by the liver. In a patient with normal renal function, its half-life is 4 hours. A patient presents with severe renal impairment, having a glomerular filtration rate that is one-third of normal. Assuming Vd is unchanged, what is the estimated new half-life of the drug in this patient?
- 8 hours
- 10 hours (correct answer)
- 12 hours
- 20 hours
Explanation: Let the normal total clearance be CL_T. Then CL_renal = 0.9 * CL_T and CL_hepatic = 0.1 * CL_T. In the patient with renal impairment, the new renal clearance is (1/3) * CL_renal = (1/3) * (0.9 * CL_T) = 0.3 * CL_T. Hepatic clearance is unchanged. The new total clearance is CL_new = (new CL_renal) + CL_hepatic = (0.3 * CL_T) + (0.1 * CL_T) = 0.4 * CL_T. Since half-life is inversely proportional to clearance (t1/2 ∝ 1/CL), the new half-life will be t1/2_new = t1/2_normal * (CL_T / CL_new) = 4 hours * (CL_T / (0.4 * CL_T)) = 4 hours * (1 / 0.4) = 4 hours * 2.5 = 10 hours.
Question 16
A maintenance dose regimen of 100 mg every 8 hours is designed to maintain an average steady-state concentration of 10 mg/L. If the patient's clearance of this drug decreases by 50% due to worsening renal function, what new dose, administered every 8 hours, would be required to maintain the same target concentration?
- 50 mg (correct answer)
- 25 mg
- 100 mg
- 200 mg
Explanation: When you encounter dosing questions involving changes in clearance, remember that steady-state concentration is directly proportional to dose and inversely proportional to clearance: Css=CL×τDose×F
Let's work through this systematically. Initially, 100 mg every 8 hours maintains 10 mg/L at steady state. When clearance decreases by 50%, the new clearance becomes half the original value. Since concentration is inversely related to clearance, if clearance halves while keeping the same dose, the concentration would double to 20 mg/L.
To maintain the target concentration of 10 mg/L with the reduced clearance, you need to proportionally reduce the dose. Since clearance decreased by 50%, the dose must also decrease by 50%: 100 mg × 0.5 = 50 mg.
Looking at the options: A) 50 mg is correct—this maintains the same concentration with half the clearance. B) 25 mg would result in a concentration of only 5 mg/L, which is too low. C) 100 mg would double the target concentration to 20 mg/L since clearance is halved. D) 200 mg would quadruple the concentration to 40 mg/L, creating potential toxicity.
Study tip: Remember the inverse clearance-dose relationship for steady-state problems. When clearance changes by a factor, adjust the dose by the same factor in the same direction to maintain target concentrations. This principle is crucial for dose adjustments in renal or hepatic impairment. Question 17
A patient is switched from an intravenous to an oral formulation of the same drug. The IV dose was 50 mg every 6 hours. The oral formulation has a bioavailability of 40%. To achieve the same average steady-state concentration, what should the oral dose be if administered every 12 hours?
- 100 mg
- 125 mg
- 500 mg
- 250 mg (correct answer)
Explanation: When you encounter dosing conversion problems, you're dealing with the fundamental principle that steady-state drug concentrations depend on the rate of drug input into the system. To maintain equivalent therapeutic effects, you must ensure the same amount of bioavailable drug reaches systemic circulation per unit time.
Start by calculating the current bioavailable dose rate from IV administration. Since IV drugs have 100% bioavailability, the patient receives 50 mg every 6 hours, which equals 6 hours50 mg=8.33 mg/hour of bioavailable drug.
For oral dosing every 12 hours to achieve this same rate, you need: Oral dose×0.40 bioavailability=8.33 mg/hour×12 hours
This gives you: Oral dose×0.40=100 mg
Therefore: Oral dose=0.40100 mg=250 mg
Choice A (100 mg) represents the total bioavailable drug needed over 12 hours but ignores the 40% bioavailability factor. Choice B (125 mg) appears to result from incorrectly doubling the IV dose and applying bioavailability backwards. Choice C (500 mg) likely comes from incorrectly calculating the bioavailability adjustment as multiplication rather than division.
Remember this formula: when switching routes, maintain the same bioavailable dose rate by dividing the required bioavailable amount by the new route's bioavailability fraction. Always account for both dosing interval changes and bioavailability differences simultaneously. Question 18
A drug's elimination follows capacity-limited (Michaelis-Menten) kinetics. The drug is administered via continuous infusion. If the infusion rate is increased from a rate well below the Km to a rate that approaches the Vmax, what will be the most significant consequence for the time required to reach a steady state?
- The time to steady state will decrease because the drug concentration increases faster.
- The time to steady state will remain dependent only on the initial half-life.
- The time to steady state will increase disproportionately, possibly taking weeks or months. (correct answer)
- A true steady state will never be reached, regardless of the infusion rate.
Explanation: For drugs with capacity-limited elimination, as the dosing rate approaches the maximum rate of elimination (Vmax), the clearance of the drug decreases. This means the 'effective' half-life increases as concentrations rise. The time to reach steady state is a function of this effective half-life. As the system becomes saturated, the half-life prolongs dramatically, and thus the time to reach a new steady state increases disproportionately. It can take an extremely long time to reach steady state, and small changes in dose can lead to large changes in steady-state concentration.
Question 19
A new antiepileptic drug is administered as 500 mg tablets, which have an oral bioavailability of 70%. The drug's volume of distribution is 50 L and its clearance is 4 L/hr. To rapidly achieve a therapeutic concentration of 14 mg/L, what is the most appropriate oral loading dose?
- 500 mg (1 tablet)
- 700 mg (1.4 tablets)
- 1400 mg (2.8 tablets)
- 1000 mg (2 tablets) (correct answer)
Explanation: Loading dose calculations are fundamental in pharmacology when you need to quickly achieve therapeutic drug concentrations. The key principle is that loading dose equals the desired concentration multiplied by the volume of distribution, then adjusted for bioavailability.
To find the oral loading dose, use this formula: Oral Loading Dose=BioavailabilityTarget Concentration×Volume of Distribution
Plugging in the values: Oral Loading Dose=0.7014 mg/L×50 L=0.70700 mg=1000 mg
This confirms that D) 1000 mg (2 tablets) is correct.
Let's examine why the other options are wrong:
A) 500 mg represents just one tablet without any pharmacokinetic calculations—this ignores both the target concentration and bioavailability considerations.
B) 700 mg is the result you'd get if you forgot to account for bioavailability (14 × 50 = 700), but since only 70% is absorbed, you need a higher oral dose.
C) 1400 mg appears to double the target concentration calculation, possibly confusing this with maintenance dose calculations or applying bioavailability incorrectly.
Study tip: Always remember that oral loading doses must be higher than IV loading doses due to incomplete absorption. When bioavailability is less than 100%, divide your calculated dose by the bioavailability fraction to determine the actual amount you need to administer orally. Question 20
A drug is administered orally every 12 hours. Its half-life is 12 hours, and it follows first-order kinetics. The dosing regimen is changed to give the same total daily dose, but now administered every 24 hours (i.e., double the dose, once a day). How will this change affect the average steady-state concentration (Css,avg) and the fluctuation between peak and trough concentrations at steady state?
- Css,avg will remain the same, but fluctuation will decrease.
- Css,avg will increase, and fluctuation will increase.
- Css,avg will remain the same, but fluctuation will increase. (correct answer)
- Css,avg will decrease, and fluctuation will decrease.
Explanation: The average steady-state concentration (Css,avg) is determined by the total daily dose (dosing rate) and clearance. Since the total daily dose is unchanged, the Css,avg will also remain the same. However, the fluctuation (the difference between peak and trough concentrations) is highly dependent on the dosing interval relative to the half-life. By doubling the dosing interval from 12 hours (1 half-life) to 24 hours (2 half-lives), more drug will be eliminated between doses, leading to a lower trough, and a larger dose will be given, leading to a higher peak. Therefore, the fluctuation will increase significantly.